US medical cannabis registries rarely track safety outcomes or patient demographics

Only 8% of US medical cannabis registries reported patient race/ethnicity, 11% tracked adverse events, and 6% reported therapeutic benefits, revealing major gaps in public health surveillance of medical cannabis.

Boehnke, Kevin F et al.·American journal of public health·2024·lowecological study
RTHC-05144Ecological studylow2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
ecological study
Evidence
low
Sample
Not reported

What This Study Found

Among 36 states with medical cannabis programs, 97% reported patient numbers and 75% reported authorizing clinicians. Least reported: patient race/ethnicity (8%), adverse events (11%), therapeutic benefits (6%), and product recalls (6%). Newer programs (2013-2018) reported more subcategories (median 11 vs. 8).

Key Numbers

36 states analyzed. Patient numbers: 97%. Clinician numbers: 75%. Race/ethnicity: 8%. Adverse events: 11%. Therapeutic benefits: 6%. Product recalls: 6%. Newer programs: median 11 subcategories vs. 8 for early adopters.

How They Did This

Analysis of 2021 medical cannabis registry reports from 34 states, Puerto Rico, and DC. Data manually coded into domains including patient demographics, clinician data, sales, and health/safety outcomes.

Why This Research Matters

Without tracking adverse events, therapeutic benefits, or patient demographics, states cannot assess whether medical cannabis is safe, effective, or equitably accessible. This is a fundamental gap in public health surveillance.

The Bigger Picture

Medical cannabis is unique among therapeutic interventions in how little post-market surveillance occurs. Prescription drugs have FDA adverse event reporting, but medical cannabis programs largely operate without comparable safety monitoring.

What This Study Doesn't Tell Us

Relies on publicly available reports which may not reflect all data collected. States may collect but not publish some data. One-year snapshot (2021). Cannot assess data quality within reported categories.

Questions This Raises

  • ?Should federal standards mandate minimum data reporting for medical cannabis registries?
  • ?Could standardized reporting across states enable population-level safety analysis?

Trust & Context

Key Stat:
Only 8% tracked patient race/ethnicity
Evidence Grade:
Comprehensive analysis of publicly available registry data with systematic coding, but limited by what states choose to report.
Study Age:
2024 analysis of 2021 state medical cannabis registry reports
Original Title:
Data Quality in State Registry Reports of Medical Cannabis Patients in the United States.
Published In:
American journal of public health, 114(S8), S685-S693 (2024)
Database ID:
RTHC-05144

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Do states track whether medical cannabis is helping patients?

Rarely. Only 6% of state registries reported data on therapeutic benefits, and only 11% tracked adverse events. Most reporting focused on patient numbers and sales data.

Do newer medical cannabis programs report better data?

Yes. States that legalized medical cannabis between 2013-2018 reported a median of 11 data subcategories compared to 8 for early-adopting states (1996-2012).

Read More on RethinkTHC

Cite This Study

RTHC-05144·https://rethinkthc.com/research/RTHC-05144

APA

Boehnke, Kevin F; Sinclair, Rachel; Gordon, Felicia; Roehler, Douglas R; Smith, Tristin; Hoots, Brooke. (2024). Data Quality in State Registry Reports of Medical Cannabis Patients in the United States.. American journal of public health, 114(S8), S685-S693. https://doi.org/10.2105/AJPH.2024.307728

MLA

Boehnke, Kevin F, et al. "Data Quality in State Registry Reports of Medical Cannabis Patients in the United States.." American journal of public health, 2024. https://doi.org/10.2105/AJPH.2024.307728

RethinkTHC

RethinkTHC Research Database. "Data Quality in State Registry Reports of Medical Cannabis P..." RTHC-05144. Retrieved from https://rethinkthc.com/research/boehnke-2024-data-quality-in-state

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.